Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

<< Previous

Bullboard Posts

Next >>

Post by bluemoons20on Mar 12, 2024 12:38pm

64 Views

Post# 35928671

Future??

Options are not looking that good. However, you would think that given the amount of money poured into RP in the last while, the folks must have had a Plan B. Things could not all have been hanging on the arbitration??,

Lets hope they get whatever worked out soon and we can all be happy!!

GLTA

<< Previous

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition